linvencorvir

RO7049389 (linvencorvir) is an investigational small molecule oral drug developed for the treatment of chronic hepatitis B virus (HBV) infection. It acts as a core protein allosteric modulator (CpAM), binding to the HBV core protein and inducing incorrect capsid assembly, which suppresses viral replication and leads to depletion of functional core protein. This mechanism is distinct from currently approved therapies for HBV, such as interferons or nucleotide analogues. Preclinical studies have shown potent antiviral activity with high selectivity against HBV. Clinical trials have demonstrated that RO7049389 is generally safe and well tolerated in both healthy volunteers and patients with chronic hepatitis B[1][2][3][6].

Other names

linvencorvirRG7907RG-7907RG 7907RO7049389RO-7049389RO 7049389